On January 20 , Reuters reported that AstraZeneca announced a major restructuring of its listing : the company will delist its American Depositary Receipts ( ADS ) and debt securities from Nasdaq and directly list its common stock and debt products on the New York Stock Exchange. The changes will take effect after the close of trading on January 30 , 2026 .
It is understood that AstraZeneca 's common stock and debt securities are expected to begin trading on the NYSE on February 2 , and will continue to use the stock code "AZN" to ensure trading continuity for investors.
This restructuring of the listing structure is a core component of the unified listing plan approved by AstraZeneca shareholders. Following the implementation of the unified structure, AstraZeneca will shift from trading ADSs (representing its common stock at a 2-to-1 ratio) to directly listing its $0.25 common stock, thereby simplifying its multi-market trading setup.
Regarding this matter, industry sources revealed last year that the market speculated the pharmaceutical company might relocate its listing to the United States. In September 2025, AstraZeneca stated in a press release that the company (AZN.US) planned to list on the New York Stock Exchange to attract more investors, but would retain its London stock trading operations and UK headquarters. CEO Pascal Soriot has long been dissatisfied with the UK's regulatory system and worried that the UK is falling behind the US and China in terms of competitiveness. Pharmaceutical companies are increasingly disappointed with the UK government's efforts to promote the development of its life sciences industry, raising objections in multiple areas, from the number of clinical trials to new drug reimbursement policies.

https://bydrug.pharmcube.com/news/detail/41884b9cc4f70b39b603ed525eb8d677